485 patents
Page 17 of 25
Utility
Modulators of the integrated stress pathway
14 Dec 20
Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.
Marina Pliushchev, Jennifer M. Frost, Lawrence A. Black, Xiangdong Xu, Ramzi Farah Sweis, Lei Shi, Qingwei I. Zhang, Yunsong Tong, Charles W. Hutchins, Seungwon Chung, Michael J. Dart
Filed: 4 May 17
Utility
PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
9 Dec 20
The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis and atopic dermatitis), kits, methods of synthesis, and products-by-process.
Aileen L. Pangan, Henrique D. Teixeira, Ayman D. Allian, Thomas B. Borchardt, Jayanthy Jayanth, Patrick J. Marroum, Fredrik Lars Nordstrom, Ahmad Y. Sheikh, Mohamed-Eslam F. Mohamed, Ahmed A. Othman, Peter T. Mayer, Ben KLÜNDER
Filed: 18 Dec 19
Utility
Stable Dual Variable Domain Immunoglobulin Protein Formulations
9 Dec 20
The invention provides stable aqueous formulations comprising an Aqueous Stable Dual Variable Domain Immunoglobulin (AS-DVD-Ig) protein.
Michael Siedler, Vineet Kumar, Ravi Chari, Sonal Saluja, Vishwesh Patil
Filed: 16 Jan 20
Utility
Automatic injection device
7 Dec 20
A syringe carrier for use within an automatic injection device includes a substantially tubular body having a first end, a middle portion, and a second end, configured to contain a portion of a syringe and displace the syringe within a housing of the automatic injection device from a first position to a second position; a first pair of legs defining at least a portion of a front opening in the substantially tubular body proximal to the first end; a second pair of legs defining at least a portion of a rear opening in the substantially tubular body proximal to the first end; and a syringe carrier coupler having a first beam and a second beam extending from the middle portion partially beyond the first pair of legs at the first end of the substantially tubular body.
Sherwin S. Shang, Joseph F. Julian, Chuan Li, Eduard N. Tsvirko, Edwin Chim, Shubha Chethan Somashekar, Esra Ozdaryal
Filed: 24 May 18
Utility
Protein tyrosine phosphatase inhibitors and methods of use thereof
30 Nov 20
Provided herein are compounds, compositions, and methods useful for inhibiting protein tyrosine phosphatase, e.g., protein tyrosine phosphatase non-receptor type 2 (PTPN2) and/or protein tyrosine phosphatase non-receptor type 1 (PTPN1), and for treating related diseases, disorders and conditions favorably responsive to PTPN1 or PTPN2 inhibitor treatment, e.g., a cancer or a metabolic disease.
Geoff T. Halvorsen, Jennifer M. Frost, Philip R. Kym
Filed: 3 Jun 20
Utility
CorrectedMethods for Treating HCV
25 Nov 20
The present invention features interferon-free therapies for the treatment of HCV.
Christine Collins, Bo Fu, Abhishek Gulati, Jens Kort, Matthew Kosloski, Yang Lei, Chih-Wei Lin, Ran Liu, Federico Mensa, Iok Chan Ng, Tami Pilot-Matias, David Pugatch, Nancy S. Shulman, Roger Trinh, Rolando M. Viani, Stanley Wang, Zhenzhen Zhang
Filed: 1 Aug 17
Utility
Ibrutinib Combination Therapy
25 Nov 20
Combinations of Bruton's tyrosine kinase (Btk) inhibitors, e.g., 1-((R)-3-(4-amino-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, with a second anticancer agent are provided.
Betty Chang, Sriram Balasubramanian, Richard Crowley, Hsu-Ping Kuo, Brett Hall, Kate A. Sasser, Tineke Casneuf, Michael Schaffer, Matthias Versele, Willem Ligtenberg, Cue Davis
Filed: 31 Jul 19
Utility
Methods of Treating Glioblastoma
25 Nov 20
The present disclosure provides a method for treating cancer in a patient harboring an EGFR-expressing tumor and/or tumor cell, such as glioblastoma, comprising the combination of (i) applying an AC electric field to a target area, wherein the target area comprises an EGFR-expressing tumor or cancer cell); and (ii) administering an effective amount of depatuxizumab mafodotin.
David MAAG, Moshe GILADI, Rosa S. SCHNAIDERMAN, Einav ZEEVI, Eilon KIRSON
Filed: 18 Nov 18
Utility
Anti-CD40 antibody
23 Nov 20
The present disclosure provides novel anti-CD40 antibodies, compositions including the new antibodies, nucleic acids encoding the antibodies, and methods of making and using the same.
Diane Sau Mun Cohen, Diane Hollenbaugh, Shiming Ye
Filed: 2 Sep 19
Utility
Modulators of the Integrated Stress Pathway
18 Nov 20
Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.
Kathleen Ann Martin, Carmela Sidrauski, Marina Pliushchev, Yunsong Tong, Xiangdong Xu, Qingwei I. Zhang, Ramzi Farah Sweis, Michael J. Dart
Filed: 1 Nov 18
Utility
Modulators of the Integrated Stress Pathway
18 Nov 20
Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.
Kathleen Ann Martin, Carmela Sidrauski, Marina Pliushchev, Jennifer M. Frost, Yunsong Tong, Lawrence A. Black, Xiangdong Xu, Lei Shi, Qingwei I. Zhang, SeungWon Chung, Zhaoming Xiong, Ramzi Farah Sweis, Michael J. Dart, Brian S. Brown, Kathleen J. Murauski
Filed: 1 Nov 18
Utility
PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
18 Nov 20
The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.
Jayanthy Jayanth, Ben Klünder, Mohamed-Eslam Mohamed, Ahmed A. Othman, Patrick J. Marroum, Peter T. Mayer
Filed: 2 Aug 20
Utility
Salts and Crystalline Forms of an Apoptosis-inducing Agent
18 Nov 20
Salts and crystalline forms of 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}-sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide are suitable active pharmaceutical ingredients for pharmaceutical compositions useful in treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.
Nathaniel Catron, Shuang Chen, Yuchuan Gong, Geoff G. Zhang
Filed: 30 Jul 20
Utility
Organic reactions carried out in aqueous solution in the presence of a hydroxyalkyl(alkyl)cellulose or an alkylcellulose
16 Nov 20
The present invention relates to a method of carrying out an organic reaction in aqueous solution in the presence of a hydroxyalkyl(alkyl)cellulose or an alkylcellulose.
Wilfried Braje, Katarina Britze, Justin D. Dietrich, Anais Jolit, Johannes Kaschel, Johanna Klee, Tanja Lindner
Filed: 13 Jan 20
Utility
Modulators of the integrated stress pathway
16 Nov 20
Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.
Marina Pliushchev, Jennifer M. Frost, Lawrence A. Black, Xiangdong Xu, Ramzi Farah Sweis, Lei Shi, Qingwei I. Zhang, Yunsong Tong, Charles W. Hutchins, Seungwon Chung, Michael J. Dart
Filed: 4 May 17
Utility
Anti-PTK7 antibodies and methods of use
16 Nov 20
Anti-PTK7 modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat hyperproliferative disorders are provided.
Orit Foord, Scott J. Dylla, Robert A. Stull, Alex Bankovich, Alexandra Leida Liana Lazetic, Jeffrey Bernstein
Filed: 28 Jan 18
Reissue
Fused heterocyclic derivatives as S1P modulators
9 Nov 20
This invention relates to new fused heterocyclic derivatives having affinity to S1P receptors, a pharmaceutical composition containing said compounds, as well as the use of said compounds for the preparation of a medicament for treating, alleviating or preventing diseases and conditions in which any S1P receptor is involved or in which modulation of the endogenous S1P signaling system via any S1P receptor is involved.
Pieter Smid, Wouter I. Iwema Bakker, Hein K. A. C. Coolen, Leonardus A. J. M. Sliedregt, Maria J. P. van Dongen, Jacobus A. J. den Hartog, Adrian Hobson
Filed: 29 Jan 19
Utility
Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor
9 Nov 20
Described herein are pharmaceutical formulations of Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one.
Ching W. Chong, Robert Kuehl, Heow Tan, Harisha Atluri
Filed: 9 Apr 20
Utility
Apoptosis-inducing Agents for the Treatment of Cancer and Immune and Autoimmune Diseases
4 Nov 20
Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-xL protein.
Le WANG, George DOHERTY, Xilu WANG, Zhi-Fu TAO, Milan BRUNCKO, Aaron R. KUNZER, Michael D. WENDT, Xiaohong SONG, Robin FREY, Todd M. HANSEN, Gerard M. SULLIVAN, Andrew JUDD, Andrew SOUERS
Filed: 17 Dec 19
Utility
Modulators of the Integrated Stress Pathway
4 Nov 20
Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.
Kathleen Ann Martin, Carmela Sidrauski, Jennifer M. Frost, Marina Pliushchev, Yunsong Tong, Lawrence A. Black, Xiangdong Xu, Lei Shi, Qingwei I. Zhang, SeungWon Chung, Ramzi Farah Sweis, Michael J. Dart, John T. Randolph, Kathleen J. Murauski
Filed: 1 Nov 18